SAN FRANCISCO--Four months after Biogen swiftly slashed 880 jobs in a wrenching restructuring, the biotech trendsetter is back on a new hiring spree in research aimed at luring in a wave of top talent in neuroscience R&D.
BioLineRx has become the latest company to stake its claim for a spot on the burgeoning roster of immuno-oncology combinations. The small biotech is aiming to muscle into the sector by showing its CXCR4 antagonist BL-8040 can boost the effectiveness of Merck's Keytruda in metastatic pancreatic adenocarcinoma.
Spark Therapeutics, at work on gene therapies for rare diseases, laid out an ambitious three-year plan that would see its top candidate win FDA approval and 9 others enter clinical trials.
Vice President Joe Biden fleshed out his plans to take the lead on a global effort to bolster cancer research, hoping to unite industry and academia to push new therapies forward.
Robert Califf, a Duke University cardiologist in line to become the next FDA commissioner, won over a Senate panel and is on his way to final confirmation, slated to follow Margaret Hamburg as head of the agency.
German pharma giant Boehringer Ingelheim is wagering up to $262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to spotlight new treatments for central nervous system disorders.
Novartis is on the verge of offloading its former R&D site in Horsham, U.K., to the local council. The agreement of initial terms with West Sussex council comes 8 months after the University of Brighton backed out of a deal because it was unable to secure government funding.
Cardiorentis has raised CHF 60 million ($60 million). The investment bolsters the biotech's bank balance at a time when it is nearing the end of a Phase III trial of its drug for acute decompensated heart failure, data from which are due to be submitted to regulators later this year.
Novimmune has tapped existing investors for CHF 30 million ($30 million) to support the advance of its pipeline, particularly a therapy for a rare immune system disorder that is making its way through Phase II. The fundraising brings the total raised by the company in its 18-year history up to $245 million.
Pfizer, wending toward a record-setting $160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry insiders.
Israeli drug developer BioLineRx is partnering with Merck to see whether its in-development cancer therapy can work in tandem with an approved treatment that taps the power of the immune system, joining a long list of clinical partners.
Aelix Therapeutics has raised €11.5 million ($12.6 million) to advance a therapeutic HIV candidate to clinical proof of concept. Ysios Capital, Johnson & Johnson and others backed the round, having been persuaded that Aelix's immunotherapy has the potential to be a functional cure for HIV.
Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease.
Partners Roche and AbbVie are speeding toward FDA approval with a cancer treatment tabbed as a potential blockbuster, picking up a priority review for a blood cancer therapy.
South San Francisco's Iconic Therapeutics raised $40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with its ocular melanoma program.
Ophthalmology biotech Kodiak Sciences raised $34 million in Series B financing to speed up its pipeline of ocular therapies.
Moderna Therapeutics, a superlatively well-funded private biotech, has made the leap from preclinical bluster to first-in-human trials, testing out its inaugural candidate and planning to move 5 more into the clinic this year.
Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune system attack on cancer.
Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape gets more and more competitive.
In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.